Janux Therapeutics’ (JANX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note published on Monday,Benzinga reports. The firm currently has a $70.00 target price on the stock.

A number of other brokerages have also issued reports on JANX. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. BTIG Research increased their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Scotiabank decreased their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $88.00.

Janux Therapeutics Trading Up 5.0 %

NASDAQ:JANX opened at $31.50 on Monday. The firm has a market capitalization of $1.65 billion, a PE ratio of -26.92 and a beta of 3.16. The stock has a 50 day moving average of $42.23 and a 200-day moving average of $47.67. Janux Therapeutics has a 52 week low of $29.63 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at $17,583,240. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,002 shares of company stock worth $2,684,703 over the last quarter. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics during the fourth quarter worth $59,000. Plato Investment Management Ltd increased its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in Janux Therapeutics during the fourth quarter worth $139,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.